Chemed Gestion
Gestion contrôle des critères 3/4
Le PDG Chemed est Kevin McNamara, nommé en Aug1994, a un mandat de 39.58 ans. La rémunération annuelle totale est $ 12.90M, composée du salaire de 14.4% et des bonus 85.6%, y compris les actions et options de la société. détient directement 0.54% des actions de la société, d'une valeur de $ 36.97M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 26.3 ans et 17.8 ans.
Informations clés
Kevin McNamara
Directeur général
US$12.9m
Rémunération totale
| Pourcentage du salaire du PDG | 14.40% |
| Durée du mandat du directeur général | 32yrs |
| Propriété du PDG | 0.5% |
| Durée moyenne d'occupation des postes de direction | 26.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 17.8yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Aug 13
CHE: Dividend Growth And Activist Pressure Will Shape Balanced Return Outlook
Analysts have raised their price target for Chemed from $500 to $590, reflecting updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple. What’s in the News for Chemed Chemed declared a quarterly cash dividend of US$0.70 per share, payable on September 3, 2026, to shareholders of record as of August 17, 2026.Seeking Alpha • Aug 05
Chemed Corporation: Why A Spin-Off Could Unlock Its Hidden Value
Summary Chemed Corporation (CHE) receives a Buy rating with a $632/share target, driven by activist pressure for a spin-off to eliminate the conglomerate discount. VITAS has successfully reengineered its patient mix, sharply reducing Medicare Cap penalties and driving 8.8% revenue growth and 18.2% Adjusted EBITDA margin in Q2. Roto-Rooter faces structural margin pressure from rising digital marketing costs, but B2B expansion and operational efficiencies are expected to support future growth. Barington Capital’s activist involvement is a key catalyst, with a spin-off potentially unlocking an 18% upside by repricing both segments at fair multiples. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 29
CHE: Buybacks And Activist Pressure Will Shape Margins And Measured Returns
Analysts have lifted their price target fair value for Chemed from $474 to $501.50, citing updated assumptions on revenue growth, profit margins and future P/E that result in a higher overall valuation. What’s in the News for Chemed From April 1, 2026 to June 30, 2026, Chemed repurchased 210,000 shares for US$89.8 million, representing 1.59% of its shares, and has now completed the repurchase of 12,570,646 shares for US$2.91b under the buyback first announced on February 22, 2011.Mise à jour du récit • Jul 13
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.Mise à jour du récit • Jun 29
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.Mise à jour du récit • Jun 15
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Mise à jour du récit • Jun 01
CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Mise à jour du récit • Apr 27
CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).Mise à jour du récit • Apr 10
CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.Mise à jour du récit • Mar 27
CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).Mise à jour du récit • Mar 10
CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).Nouveau récit • Feb 27
Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Feb 24
CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).Mise à jour du récit • Feb 10
CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.Mise à jour du récit • Jan 23
CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.Article d’analyse • Jan 16
Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Article d’analyse • Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...Article d’analyse • Oct 24
Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Mise à jour du récit • Sep 03
New Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$275m |
| Mar 31 2026 | n/a | n/a | US$260m |
| Dec 31 2025 | US$13m | US$2m | US$265m |
| Sep 30 2025 | n/a | n/a | US$279m |
| Jun 30 2025 | n/a | n/a | US$290m |
| Mar 31 2025 | n/a | n/a | US$309m |
| Dec 31 2024 | US$13m | US$2m | US$302m |
| Sep 30 2024 | n/a | n/a | US$302m |
| Jun 30 2024 | n/a | n/a | US$301m |
| Mar 31 2024 | n/a | n/a | US$283m |
| Dec 31 2023 | US$13m | US$2m | US$273m |
| Sep 30 2023 | n/a | n/a | US$245m |
| Jun 30 2023 | n/a | n/a | US$226m |
| Mar 31 2023 | n/a | n/a | US$240m |
| Dec 31 2022 | US$12m | US$1m | US$250m |
| Sep 30 2022 | n/a | n/a | US$262m |
| Jun 30 2022 | n/a | n/a | US$277m |
| Mar 31 2022 | n/a | n/a | US$267m |
| Dec 31 2021 | US$12m | US$1m | US$269m |
| Sep 30 2021 | n/a | n/a | US$308m |
| Jun 30 2021 | n/a | n/a | US$303m |
| Mar 31 2021 | n/a | n/a | US$329m |
| Dec 31 2020 | US$12m | US$1m | US$319m |
| Sep 30 2020 | n/a | n/a | US$271m |
| Jun 30 2020 | n/a | n/a | US$263m |
| Mar 31 2020 | n/a | n/a | US$231m |
| Dec 31 2019 | US$10m | US$1m | US$220m |
Rémunération vs marché: La rémunération totale de Kevin ($USD 12.90M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 8.18M ).
Rémunération et revenus: La rémunération de Kevin a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Kevin McNamara (72 yo)
32yrs
Titularisation
US$12,904,720
Compensation
Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corporation since May 2001 and President since August 2, 1994. Mr. McNamara served as an Executive Vice President and Secretary of Cheme...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 32yrs | US$12.90m | 0.54% $ 37.0m | |
| Executive VP | 14.3yrs | US$3.71m | 0.046% $ 3.1m | |
| VP, Secretary & Chief Legal Officer | 6yrs | US$2.66m | 0.026% $ 1.8m | |
| Executive Vice President | 26.3yrs | US$3.21m | 0.11% $ 7.8m | |
| VP & Director | 38.5yrs | pas de données | 0.61% $ 42.0m | |
| Executive VP and President & CEO of VITAS Healthcare | 2.6yrs | US$3.05m | 0.0091% $ 619.7k | |
| VP, Chief Administrative Officer & Assistant Secretary | 31.8yrs | pas de données | pas de données | |
| Director of Investor Relations | no data | pas de données | pas de données | |
| VP & Chief Strategy Officer | no data | pas de données | pas de données | |
| Vice President & Assistant Controller | no data | pas de données | pas de données |
26.3yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de CHE est chevronnée et expérimentée (26.3 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 39.6yrs | US$12.90m | 0.54% $ 37.0m | |
| VP & Director | 41.6yrs | pas de données | 0.61% $ 42.0m | |
| Director Emeritus | 17.3yrs | US$157.02k | pas de données | |
| Independent Director | 30.6yrs | US$313.89k | 0.027% $ 1.9m | |
| Independent Chairman | 31.6yrs | US$495.03k | 0.028% $ 1.9m | |
| Independent Director | 18.3yrs | US$275.39k | 0.035% $ 2.4m | |
| Independent Director | 3.3yrs | US$275.39k | 0.0095% $ 651.8k | |
| Independent Director | 6.3yrs | US$286.39k | 0.021% $ 1.5m | |
| Independent Director | 6.3yrs | US$281.89k | 0.016% $ 1.1m | |
| Independent Director | 4yrs | US$281.89k | 0.010% $ 690.8k |
17.8yrs
Durée moyenne de l'emploi
72yo
Âge moyen
Conseil d'administration expérimenté: Le conseil d'administration de la CHE est chevronné et expérimenté ( 17.8 années d'ancienneté moyenne).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/18 02:54 |
| Cours de l'action en fin de journée | 2026/08/18 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Chemed Corporation est couverte par 10 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |